In addition, we found that RRM2 was enriched in the p53 signaling pathway, indicating that the mechanism of RRM2 in the development of prostate cancer was potentially correlated with the p53 signaling pathway, which remained unclear due to lack of experimental validation. The gene discussed is TP53; the disease is prostate carcinoma.